Xiao Tang Kong

Xiao Tang Kong is a Professor at the University of California, Irvine (UCI) School of Medicine, with joint appointments in the Department of Neurology and the Division of Hematology and Oncology. His research focuses on vaccine immunotherapy for glioblastoma (GBM), particularly evaluating autologous dendritic cell vaccines like AV-GBM-1. This phase II trial demonstrated reliable vaccine manufacturing (97% success rate) and showed prolonged median progression-free survival (10.4 months) compared to historical benchmarks, though overall survival (16.0 months) did not improve. Common adverse events included injection site reactions (16%) and CNS-related symptoms (e.g., seizures in 33% of patients).

The AV-GBM-1 vaccine utilizes autologous tumor-initiating cells and dendritic cells, aligning with trends in personalized cancer immunotherapy. Keywords include Neuro-Oncology, Immunotherapy, Glioblastoma, and Clinical Trial. Sub-fields of research encompass Dendritic Cell Vaccines, Tumor Immunology, and Cancer Survival Analysis.